New hope for Tough-to-Treat lymphoma patients in Real-World setting
NCT ID NCT07472621
Summary
This study will observe how well the drug glofitamab works for patients with aggressive lymphoma that didn't respond to initial treatment or returned quickly. Doctors will follow about 20 patients receiving this treatment as part of their regular care to see how they respond and manage side effects. The study aims to gather real-world evidence about this treatment option for difficult cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
Zhengzhou, Henan, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.